our Premium Content: News alerts, weekly reports and conference planners

GENE:

CD1D (CD1d Molecule)

News alerts, weekly reports and conference planners

4ms

Brahmi (Bacopa monnieri) plant preparation facilitates to enhance the activities of dendritic cells to control non-small cell lung cancer (NSCLC). (PubMed, J Cancer Res Clin Oncol)

Overall, these findings demonstrate the ability of BPP to influence dendritic and T-cell responses in NSCLC via coordinated transcriptional and chromatinremodelling activities.

4 months ago

Journal

TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL10 (Interleukin 10) • HDAC2 (Histone deacetylase 2) • TBX21 (T-Box Transcription Factor 21) • FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • IL4 (Interleukin 4) • STAT2 (Signal transducer and activator of transcription 2) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • CD1D (CD1d Molecule) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • STAT4 (Signal Transducer And Activator Of Transcription 4)

6ms

Integrative Analysis of TLS-Associated Gene Signatures, Immune Infiltration and Drug Sensitivity in Pancreatic Cancer. (PubMed, IET Syst Biol)

Notably, the TLS_H group demonstrated enhanced sensitivity to chemotherapeutics including AZD8055, axitinib, vorinostat, nilotinib, camptothecin and paclitaxel. Real-time fluorescent quantitative PCR (RT-qPCR) validation in Mia PaCa2 and Jurkat cells indicated that LAT, RBP5 and SKAP1 may play important roles in modulating sensitivity to these chemotherapeutics. These findings establish TLS as a potential biomarker for PAAD, enabling personalised chemotherapy selection by integrating immune contexture and genomic drivers to improve clinical outcomes.

6 months ago

Journal • Tumor mutational burden • Gene Signature

TMB (Tumor Mutational Burden) • CD79B (CD79b Molecule) • SKAP1 (Src Kinase Associated Phosphoprotein 1) • CCR6 (C-C Motif Chemokine Receptor 6) • CD1D (CD1d Molecule) • PTGDS (Prostaglandin D2 Synthase)

paclitaxel • nilotinib • axitinib • Zolinza (vorinostat) • AZD8055

1year

HSV-1 UL56 protein recruits cellular NEDD4-family ubiquitin ligases to suppress CD1d expression and NKT cell function. (PubMed, J Virol)

Rao, X. Wen, J. H. Lo, S. Kim, X. Li, et al., J Virol 92:e01490-18, 2018, https://doi.org/10.1128/jvi.01490-18), we now screened the HSV-1 expression library and identified UL56 is a key factor downregulating CD1d and suppressing NKT cell function. In this manuscript, we are reporting our molecular mechanism study of how UL56 evades CD1d antigen presentation and NKT cell function.

1 year ago

Journal

CD1D (CD1d Molecule) • NEDD4 (NEDD4 E3 Ubiquitin Protein Ligase)

1year

Bioinformatics-based analysis of the role of immune-related genes in acute rejection after kidney transplantation and renal cancer development. (PubMed, Medicine (Baltimore))

FAM3C may become a potential biological marker for AR diagnosis and plays an important role in the development of renal cancer. In summary, immune-related genes play an important role in the diagnosis of AR after kidney transplantation, and the gene FAM3C may be a potential therapeutic target for AR and renal cancer.

1 year ago

Journal

HMOX1 (Heme Oxygenase 1) • CD1D (CD1d Molecule) • FPR2 (Formyl Peptide Receptor 2)

over1year

Identification of α-galactosylceramide as an endogenous mammalian antigen for iNKT cells. (PubMed, J Exp Med)

Activity-based purification and SFC/MS/MS identified dihydrosphingosine-based saturated α-GalCer as an antigenic component in serum, bile, and lymphoid tissues. These results show the first evidence for the presence of potent antigenic α-GalCer in mammals.

over 1 year ago

Journal

CD1D (CD1d Molecule)

almost2years

Effective suppression of tumor growth and hepatic metastasis of neuroblastoma by NKT-stimulatory phenyl glycolipid. (PubMed, Biomed Pharmacother)

These immune-modulating effects of C34 might act in concert in the local milieu of liver to suppress the tumor growth. Further analysis of database of neuroblastoma revealed that patients with high CD11c expression in the monocytic MDSCs in the tumor had longer survival, suggesting the potential clinical application of C34 for treatment of neuroblastoma.

almost 2 years ago

Journal

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • ITGAX (Integrin Subunit Alpha X) • CD1D (CD1d Molecule)

2years

Role of Natural Killer T (NKT) Cells in Myeloma Biology and Therapy. (PubMed, Crit Rev Oncog)

Chronic immune activation in this setting eventually sets the stage for malignancy, which can be targeted in both mouse models and GD patients by reducing the underlying antigen. NKT cells are thus integrally linked to MM pathogenesis and an attractive target for MM immunotherapy.

2 years ago

Journal

CD1D (CD1d Molecule)

CD1D expression

2years

The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma. (PubMed, J Cancer Res Clin Oncol)

The prognostic signature constructed in this study, based on six fatty acid-related genes, exhibits strong capabilities in predicting patient outcomes, identifying the TIME, and assessing drug sensitivity. This signature can aid in patient risk stratification and provide guidance for clinical treatment strategies. Additionally, our research highlights the crucial role of CD1D in the CM's TIME, laying a theoretical foundation for future related studies.

2 years ago

Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-E (Major Histocompatibility Complex, Class I, E) • CD1D (CD1d Molecule) • HLA-C (Major Histocompatibility Complex, Class I, C)

PD-1 positive

over2years

Genomic Analyses Unveil the Pathogenesis and Inform on Therapeutic Targeting in KMT2A-PTD AML (ASH 2023)

Given the results obtained with menin inhibitors in KMT2A-rearranged and NPM1-mutated AML, our findings open an opportunity for exploiting a therapeutic vulnerability in all HOX-AML including KMT2A-PTD AML or AML with high MEN1 expression. Since HOX-AML highly express genes according to the HOX differentiation profile, stage-specific surface proteins coded by these genes would be promising targets.

over 2 years ago

Genomic analysis

FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • CD276 (CD276 Molecule) • SRSF2 (Serine and arginine rich splicing factor 2) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • PML (Promyelocytic Leukemia) • CD34 (CD34 molecule) • STAG2 (Stromal Antigen 2) • CD14 (CD14 Molecule) • LILRB4 (Leukocyte Immunoglobulin Like Receptor B4) • MEN1 (Menin 1) • CD1D (CD1d Molecule) • CD86 (CD86 Molecule) • HOXB2 (Homeobox B2) • NKX2-3 (NK2 Homeobox 3)

NPM1 mutation • TET2 mutation • KMT2A rearrangement • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • STAG2 mutation • MLL mutation • MLL translocation • KMT2A expression • KMT2A-PTD • CD1D expression

over2years

Crosstalk within peripheral blood mononuclear cells mediates anti-inflammatory effects of n-3 PUFA-rich lipid emulsions in parenteral nutrition. (PubMed, Clin Nutr)

These results show a mechanism for the beneficial effect of the n-3-rich Omegaven in patients with inflammatory conditions but questions its use in patients with cancer. Hence, our results may assist in choosing the best lipid emulsion for patients who require PN.

over 2 years ago

Journal

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CD14 (CD14 Molecule) • FOXP3 (Forkhead Box P3) • IL4 (Interleukin 4) • AVEN (Apoptosis And Caspase Activation Inhibitor) • CD1D (CD1d Molecule) • CD86 (CD86 Molecule)

IFNG expression • CD1D expression